| Year |
Citation |
Score |
| 2023 |
Mitra Ghosh T, Mazumder S, Davis J, Yadav J, Akinpelu A, Alnaim A, Kumar H, Waliagha R, Church Bird AE, Rais-Bahrami S, Bird RC, Mistriotis P, Mishra A, Yates CC, Mitra AK, et al. Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers. Cancer Research Communications. 3: 1286-1311. PMID 37476073 DOI: 10.1158/2767-9764.CRC-22-0427 |
0.539 |
|
| 2023 |
Davis JT, Ghosh TM, Mazumder S, Mitra A, Bird RC, Arnold RD. Extended Exposure Topotecan Significantly Improves Long-Term Drug Sensitivity by Decreasing Malignant Cell Heterogeneity and by Preventing Epithelial-Mesenchymal Transition. International Journal of Molecular Sciences. 24. PMID 37239838 DOI: 10.3390/ijms24108490 |
0.482 |
|
| 2022 |
Mazumder S, Mitra Ghosh T, Mukherjee UK, Chakravarti S, Amiri F, Waliagha RS, Hemmati F, Mistriotis P, Ahmed S, Elhussin I, Salam AB, Dean-Colomb W, Yates C, Arnold RD, Mitra AK. Integrating Pharmacogenomics Data-Driven Computational Drug Prediction with Single-Cell RNAseq to Demonstrate the Efficacy of a NAMPT Inhibitor against Aggressive, Taxane-Resistant, and Stem-like Cells in Lethal Prostate Cancer. Cancers. 14. PMID 36497496 DOI: 10.3390/cancers14236009 |
0.547 |
|
| 2022 |
Kumar H, Mazumder S, Sharma N, Chakravarti S, Long MD, Meurice N, Petit J, Liu S, Chesi M, Sanyal S, Stewart AK, Kumar S, Bergsagel L, Rajkumar SV, Baughn LB, ... ... Mitra AK, et al. Single-Cell Proteomics and Tumor RNAseq Identify Novel Pathways Associated With Clofazimine Sensitivity in PI- and IMiD- Resistant Myeloma, and Putative Stem-Like Cells. Frontiers in Oncology. 12: 842200. PMID 35646666 DOI: 10.3389/fonc.2022.842200 |
0.343 |
|
| 2022 |
Kumar H, Mazumder S, Chakravarti S, Sharma N, Mukherjee UK, Kumar S, Baughn LB, Van Ness BG, Mitra AK. secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics. Blood Cancer Journal. 12: 39. PMID 35264575 DOI: 10.1038/s41408-022-00636-2 |
0.324 |
|
| 2021 |
Mitra Ghosh T, Kansom T, Mazumder S, Davis J, Alnaim AS, Jasper SL, Zhang C, Bird A, Opanasopit P, Mitra AK, Arnold RD. . The Journal of Pharmacology and Experimental Therapeutics. PMID 34949650 DOI: 10.1124/jpet.121.000898 |
0.488 |
|
| 2021 |
Mitra Ghosh T, White J, Davis J, Mazumder S, Kansom T, Skarupa E, Barnett GS, Piazza GA, Bird RC, Mitra AK, Yates C, Cummings BS, Arnold RD. Identification and Characterization of Key Differentially Expressed Genes Associated With Metronomic Dosing of Topotecan in Human Prostate Cancer. Frontiers in Pharmacology. 12: 736951. PMID 34938177 DOI: 10.3389/fphar.2021.736951 |
0.552 |
|
| 2019 |
Kumar H, Mukherjee UK, Chen L, Mitra AK. In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma Blood. 134: 5543-5543. DOI: 10.1182/blood-2019-131923 |
0.351 |
|
| 2019 |
Kumar H, Mukherjee UK, Mazumder S, Sanyal S, Van Ness BG, Mitra AK. Repurposing Clofazimine As a Novel Drug for the Treatment of PI-Resistant Stem Cell-like Subclones in Myeloma Blood. 134: 4418-4418. DOI: 10.1182/blood-2019-131596 |
0.308 |
|
| 2019 |
Ghosh TM, Mitra AK, Davis J, Cummings B, Yates C, Arnold R. Abstract LB-267: Transcriptomic and epigenomic analysis of metastatic castration-resistant prostate cancer and a pan-cancer analysis of its genetic signatures Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Lb-267 |
0.355 |
|
| 2018 |
Chen L, Mukherjee UK, Rankine E, Van Ness BG, Mitra AK. Secdrug: A Computational Method for Discovering Novel Secondary Drug Combinations Using Large-Scale Pharmacogenomics Databases Blood. 132: 4473-4473. DOI: 10.1182/BLOOD-2018-99-117653 |
0.347 |
|
| 2017 |
Winterhoff BJ, Maile M, Mitra AK, Sebe A, Bazzaro M, Geller MA, Abrahante JE, Klein M, Hellweg R, Mullany SA, Beckman K, Daniel J, Starr TK. Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells. Gynecologic Oncology. PMID 28111004 DOI: 10.1016/J.Ygyno.2017.01.015 |
0.33 |
|
| 2015 |
Mitra AK, Mukherjee U, Harding T, Stessman H, Li Y, Jin J, Kumar SK, Rajkumar SV, Ness BGV. Scattome: A Single-Cell Analysis of Targeted Transcriptome Program to Predict Drug Sensitivity of Single Cells within Human Myeloma Tumors Blood. 126: 4249-4249. DOI: 10.1182/Blood.V126.23.4249.4249 |
0.3 |
|
| 2014 |
Mitra AK, Stessman H, Linden MA, Van Ness B. Single-Cell Transcriptomics Identifies Intra-Tumor Heterogeneity in Human Myeloma Cell Lines Blood. 124: 3385-3385. DOI: 10.1182/Blood.V124.21.3385.3385 |
0.305 |
|
| 2013 |
Van Ness B, Stessman HAF, Baughn LB, Mansoor A, Mitra A, Dolloff NG, Myers CL, Zhan F, Harding T. Strategies To Identify Effective Treatments For Proteasome Inhibitor Resistant Multiple Myeloma Blood. 122: 278-278. DOI: 10.1182/blood.v122.21.278.278 |
0.308 |
|
| Show low-probability matches. |